iPsomics is a promising life science start-up originating from UMCG. With support from PharmaNL, the company (formerly G2 Solutions) is building a unique infrastructure that combines human iPSC technology (induced pluripotent stem cells) with single-cell whole genome sequencing. This powerful combination enables the development of cell-level disease models and allows for much more precise study of complex diseases, such as cancer.
“By reading the DNA of individual cells, we gain a far more detailed understanding of what is happening in a tumor,” says Prof. Dr. Ir. Floris Foijer (UMCG/ERIBA, co-founder and CSO of iPsomics).
With PharmaNL support, iPsomics is developing an infrastructure that can be used by Dutch academic and industrial partners for innovative drug research. The company aims to accelerate the translation of academic innovations into clinical and commercial applications. In addition to the shared infrastructure, the start-up also conducts its own projects.
Read more via: https://www.ipsomics.com/.
